Title
Treatment Options for Thrombocytopenia in Patients with Chronic Liver Disease Undergoing a Scheduled Procedure
Publication Date
2020
Journal Title
J Clin Gastroenterol
Abstract
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. Thrombocytopenia is a consequence of portal hypertension and is the most common hematological manifestation of chronic liver disease (CLD) (ie, cirrhosis). Data indicates the rates of CLD are increasing and, as a result, so will the incidence of this complication. Although bleeding risks are only relevant when elective procedures are performed, this is a frequent concern as these procedures are commonly part of the spectrum of care for patients with cirrhosis. As such, thrombocytopenia remains a pertinent issue. Fortunately, we now have effective and accurate treatment modalities to raise platelet counts before scheduled procedures, known as thrombopoietin receptor agonists. Two drugs in this therapeutic class (avatrombopag and lusutrombopag) are now approved for the treatment of thrombocytopenia in adults with CLD undergoing a procedure and have revolutionized how this is managed. Although there is progress in the field, peer-reviewed literature and expert guidance are lacking. Recognizing these unmet needs, a group of expert hepatologists comprised this review, which summarizes the most current and relevant peer-reviewed literature on thrombocytopenia in CLD and provides clinical expertise on this timely topic.
Volume Number
54
Issue Number
6
Pages
503-511
Document Type
Article
Status
Faculty
Facility
School of Medicine
Primary Department
Hepatology
Additional Departments
Science Education
PMID
DOI
10.1097/MCG.0000000000001338